ArticlePaediatrics & child health2025
A retrospective cohort study of neonatal abstinence syndrome patients following implementation of Eat Sleep Console Protocol.
Article in Paediatrics & child health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neonatal abstinence syndrome (NAS) is a set of withdrawal symptoms experienced in a newborn if they have been exposed to substances such as opioids prior to birth. The incidence of NAS in British Columbia as well as NAS-related healthcare burden, has been increasing within the last several years. Aim: To determine whether the novel Eat, Sleep, Console (ESC) approach to NAS improves outcomes such as length of hospitalization compared to Finnegan Neonatal Abstinence Scoring System (FNASS) approach in the treatment of neonatal patients with NAS admitted to the Neonatal Intensive Care Unit (NICU). Methods: Retrospective paper and electronic chart review of neonatal patients born at ≥35 weeks gestation and ≤28 days of life with prenatal exposure to opioids and admitted to Kelowna General Hospital (KGH) Neonatal Intensive Care Unit (NICU) between January 2018 and February 2023. Results: The primary outcome of hospital length of stay was 19.5 days for the ESC group and 27.5 days for FNASS (p=0.039). Secondary outcomes of total weaning morphine doses (53 vs 147; p<0.001), percentage requiring maintenance dosing (43.8% vs 100%; p<0.001), and length of wean (8.2 vs 18.1 days; p=0.003) were significantly less with ESC. Percentage who received only as needed morphine was greater with ESC (37.5% vs 0%; p<0.001). Total morphine dose (11.2mg vs 22.5mg; p=0.09) and adverse events (6% vs 11.7%; p=0.54) were not statistically significantly different. Conclusions: Compared to FNASS, ESC approach improves several outcomes for NAS patients admitted to the NICU including a reduction in length of hospitalization by 8 days.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.